Search
for
Sort by
Research 61–90 of 1000+
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Under Development JAK Inhibitors for Dermatologic Diseases
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Baricitinib for alopecia areata
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata
- Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Alopecia areata
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Alopecia areata in children: an overview of clinical features and recent treatment options
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- Prenatal diagnosis of a foetus with partial monosomy 4p and partial trisomy 13q
- A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Alopecia Areata
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Treatment of severe alopecia areata with baricitinib
- A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen